Canada’s Drug and Health Technology Agency (CADTH) wants zero days to pass between Health Canada’s approval of a drug and their reimbursement recommendation.
The agency announced their new Target Zero initiative, which they say will “aim to improve the time to access for patients in Canada for new drugs that are proven to be effective.” CADTH plans to achieve this by increasing collaboration between stakeholder groups while reducing approval timelines.
“With Target Zero, we are demonstrating a new level of cooperation with partner organizations in Canada’s drug regulatory and reimbursement environment. The initiative provides another opportunity for us to work with Health Canada, the pharmaceutical and life science industries, the pan-Canadian Pharmaceutical Alliance, and patient and clinician groups.”
Access and time to patient is a topic we have covered in our 2024 webinar series, which you can view HERE.
To read CADTH’s full statement, click HERE.